close
Add to watchlist
YM BioSciences Inc (YMI) Healthcare, Biotechnology & Drugs
YM Biosciences, Inc., a biopharmaceutical company, develops products primarily for the treatment of patients with cancer worldwide. Its product candidates in the clinical stage of development include Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor designed to treat epithelial cancers, as well as for nasopharangeal cancer and for head and neck cancer; AeroLEF, a proprietary formulation of free and liposome-encapsulated fentanyl administered by pulmonary inhalation for the treatment of severe and moderate acute pain, including cancer pain; and Tesmilifene, a small molecule drug with multiple modes of action that demonstrated enhancement of the activity of traditional chemotherapy. The company, formerly known as York Medical, Inc., was founded in 1994 and is based in Mississauga, Canada.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 1.96 |
| Volume | 974219 |
| Volume Avg | (mio) 1.2 |
| 52 Week High | 3.78 |
| 52 Week Low | 1.03 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.13 |
| EPS change Q/Q | 0% |
| EPS change Q/Q Yr ago | -66.67% |
| EPS change Q/Q next Q est | -25% |
| EPS change Y/Y | -36.59% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | -42.86% |
| EPS next Q est | -0.08 |
| EPS next Y est | -0.25 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |